C4 Therapeutics (CCCC) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Evercore ISI Group | Maintained | Outperform | $12.00 from $7.00 | Jun 1, 2026 |
| Barclays | Maintained | Overweight | $7.00 from $5.00 | Feb 27, 2026 |
| Brookline Capital | Maintained | Buy | $30.00 from $20.00 | Feb 23, 2026 |
| Barclays | Maintained | Overweight | $5.00 from $10.00 | Dec 17, 2025 |
| TD Cowen | Initiated Coverage | Buy | — | Dec 2, 2025 |
| Barclays | Maintained | Overweight | $10.00 from $8.00 | Sep 23, 2025 |
| Wells Fargo | Maintained | Overweight | $10.00 from $5.00 | Sep 23, 2025 |
| Stephens & Co. | Maintained | Overweight | $6.00 | Sep 22, 2025 |
| Barclays | Initiated Coverage | Overweight | $8.00 | Sep 17, 2025 |
| Stephens & Co. | Upgraded | Equal-Weight → Overweight | $6.00 from $3.00 | Sep 15, 2025 |
| Guggenheim | Initiated Coverage | Buy | $8.00 | Sep 4, 2025 |
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $12.00 from $8.00 | Dec 19, 2024 |
| Stephens & Co. | Initiated Coverage | Equal-Weight | $4.00 | Nov 18, 2024 |
| BMO Capital | Maintained | Outperform | $20.00 | Aug 6, 2024 |
| Stifel | Maintained | Buy | $14.00 from $13.00 | May 9, 2024 |
| Wells Fargo | Maintained | Equal-Weight | $8.00 from $7.00 | May 9, 2024 |
| Morgan Stanley | Maintained | Equal-Weight | $8.00 from $1.00 | Feb 26, 2024 |
| Stifel | Maintained | Buy | $13.00 from $12.00 | Feb 23, 2024 |
| JP Morgan | Upgraded | Underweight → Neutral | $6.00 | Jan 29, 2024 |
| Stifel | Upgraded | Hold → Buy | $12.00 from $2.00 | Dec 13, 2023 |
Frequently asked questions
Is CCCC a buy, sell, or hold?
Analysts covering C4 Therapeutics currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CCCC?
On Jun 1, 2026, Evercore ISI Group maintained C4 Therapeutics at Outperform with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.